Cancer Chemo-Immunotherapy In article number 2103497, Yubin Huang, Dongfang Zhou, and co-workers demonstrate an engineered endogenous tumor-associated macrophages (TAMs)-targeting biomimetic nano-red-blood-cell (RBC) system to deliver chemotherapeutic doxorubicin oxygen for enhanced cancer chemo-immunotherapy. TAMs-targeting depletion hypoxia alleviation synergistically reprogram the tumor immu...

Immunotherapy In article 2212267, Haihua Xiao, Nianzeng Xing, and co-workers present a novel therapeutic strategy to achieve synergistic cancer immunotherapy via cuproptosis induced by reactive oxygen species (ROS)-responsive nanomedicine loaded with elesclomol copper ([email protected]). With this approach, the tumor microenvironment is reprogrammed, expression of PD-L1 increased, which conseq...

background: bacterial superantigen staphylococcal enterotoxins (ses), has stimulated polyclonal t cells irrespective of their antigen specificity, resulted a massive release of cytokines, and suggested that they could be assigned as a candidate of new antitumor agents. recent attempts have done to specifically target superantigens towards tumors, subsequently monoclonal antibodies and tumor-rel...

Developers of cancer immunotherapy have struggled for decades to achieve clinical success in using the patient's immune system to treat cancer. In the absence of a defined development paradigm for immunotherapies, conventional criteria established for chemotherapy were applied to these agents. This article summarizes the recent lessons for development of agents in the immunotherapy space, descr...

BACKGROUND Immunotherapy has become an attractive new strategy in the treatment of cancer. The laboratory and clinical study of cancer immunotherapy is rapidly advancing. However, in the clinical setting, the results of cancer immunotherapy are mixed. We therefore contend that cancer immunotherapy should be customized to each patient individually based on their immune status and propose an inte...

In order to approach human cancer immunotherapy, the author carried out the immunotherapy with BCG on mice having homotransplanted cancer, observed the posttransplantation results with lapse of time, conduced daily macrophage inhibition test (MI test) and found the immunotherapy to be effective. At the same time the MI test proved to be a useful criterion in determining the course of cancer pro...

background: the adjuvanticity potential of lactobacillus casei was first suggested in an old survey. the present study was designed to investigate the efficacy of a new immunotherapy against breast cancer made by mixing an extract of heated 4t1 mammary carcinoma cell line and a heat-killed preparation of lactobacillus casei. methods: female balb/c mice (6–8 weeks old, n=40) were challenged subc...

The immune system is able to specifically target antigen-expressing cancer cells. The promise of immunotherapy was to eliminate cancer cells without harming normal tissue and, therefore, with no or very few side effects. Immunotherapy approaches have, for several decades, been tested against several tumours, most often against malignant melanoma. However, although detectable immune responses ha...

Immunotherapy for colorectal cancer has been under investigation for many years. Many recent scientific advances contribute to the success of cancer immunotherapy, including our better understanding of anti-tumor immune response, tolerance and regulation, and the advent of newer therapies including agonist antibodies to the co-stimulatory molecules targeting T cells. Immunotherapy may represent...

background: it seems that the success of vaccination for cancer immunotherapy such as dendritic cell (dc) based cancer vaccine is hindered through a powerful network of immune system suppressive elements in which regulatory t cell is the common factor. foxp3 transcription factor is the most specific marker of regulatory t cells. in different studies, targeting an immune response against regulat...